ELZONRIS

Serial Number 87843152
Registration 5782895
702

Registration Progress

Application Filed
Mar 21, 2018
Under Examination
Apr 9, 2019
Approved for Publication
Feb 12, 2019
Published for Opposition
Feb 12, 2019
Registered
Jun 18, 2019

Attorney Assistance

Section 8 (6-Year) Declaration Due (Based on registration date 2019-06-18) (Grace Period Filing)
Due: Dec 18, 2025 Grace Period - 43 days
Original deadline was Jun 18, 2025 (overdue)

Trademark Image

ELZONRIS

Basic Information

Serial Number
87843152
Registration Number
5782895
Filing Date
March 21, 2018
Registration Date
June 18, 2019
Published for Opposition
February 12, 2019
Drawing Code
4

Status Summary

Current Status
Active
Status Code
702
Status Date
Oct 4, 2025
Registration
Registered
Classes
005

Rights Holder

Stemline Therapeutics, Inc.

03
Address
750 Lexington Avenue, 11th Floor
New York, NY 10022

Ownership History

Stemline Therapeutics, Inc.

Original Applicant
03
New York, NY

Stemline Therapeutics, Inc.

Owner at Publication
03
New York, NY

Stemline Therapeutics, Inc.

Original Registrant
03
New York, NY

Legal Representation

Attorney
Maury M. Tepper, III

USPTO Deadlines

Next Deadline
In Grace Period
Section 8 (6-Year) Declaration Due (Based on registration date 2019-06-18)
Due Date
June 18, 2025
Grace Period Ends
December 18, 2025
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

30 events
Date Code Type Description Documents
Oct 4, 2025 NA85 E NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED Loading...
Oct 4, 2025 C15A O REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. Loading...
Oct 4, 2025 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL Loading...
Jun 2, 2025 E815 I TEAS SECTION 8 & 15 RECEIVED Loading...
Jun 18, 2024 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Loading...
Jun 18, 2019 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
May 16, 2019 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
May 15, 2019 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Apr 23, 2019 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Apr 23, 2019 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Apr 10, 2019 IUAF S USE AMENDMENT FILED Loading...
Apr 10, 2019 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Apr 9, 2019 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Feb 18, 2019 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Feb 18, 2019 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Feb 12, 2019 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 12, 2019 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 23, 2019 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jan 9, 2019 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Jan 7, 2019 ALIE A ASSIGNED TO LIE Loading...
Dec 13, 2018 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 12, 2018 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 12, 2018 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 12, 2018 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jul 3, 2018 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jul 3, 2018 DOCK D ASSIGNED TO EXAMINER Loading...
Jul 3, 2018 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jul 3, 2018 GNRT F NON-FINAL ACTION E-MAILED Loading...
Mar 28, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Mar 24, 2018 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
pharmaceutical preparations for the diagnosis and treatment of cancer and auto-immune diseases; drug delivery agent in the form of infusion for the diagnosis and treatment of cancer and auto-immune diseases
First Use Anywhere: Jan 23, 2019
First Use in Commerce: Jan 23, 2019

Additional Information

Translation
The wording "ELZONRIS" has no meaning in a foreign language.

Classification

International Classes
005